BFEC
APTO

Benjamin F. Edwards & Company’s Aptose Biosciences, Inc. APTO Stock Holding History

Benjamin F. Edwards & Company’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-44
Closed -$12K – 1929
2022
Q3 		$12K Hold
44
– – ﹤0.01% 1367
2022
Q2 		$15K Hold
44
– – ﹤0.01% 1302
2022
Q1 		$27K Hold
44
– – ﹤0.01% 1174
2021
Q4 		$27K Hold
44
– – ﹤0.01% 1180
2021
Q3 		$44K Buy
44
+26
+144% +$32.5K ﹤0.01% 1060
2021
Q2 		$27K Buy
+18
New +$39.2K ﹤0.01% 1165
2021
Q1 		– Sell
-22
Closed -$44K – 1752
2020
Q4 		$44K Buy
+22
New +$51.7K ﹤0.01% 996

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $709M AUM 11.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Benjamin F. Edwards & Company's APTO Position: Q4 2022 in Review

Benjamin F. Edwards & Company sold out of Aptose Biosciences, Inc. (APTO) in Q4 2022, closing a stake of 44 shares — an estimated $12K sold.

Benjamin F. Edwards & Company first reported a position in APTO in Q4 2020 and held it in 7 quarters. The position peaked at $44K in Q3 2021. 47 funds tracked by Wall St. Rank hold APTO as of Q4 2022.

  • Benjamin F. Edwards & Company reported no remaining Aptose Biosciences, Inc. position as of Q4 2022 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 44 Aptose Biosciences, Inc. shares in Q4 2022, an estimated $12K.
  • Benjamin F. Edwards & Company first reported a position in Aptose Biosciences, Inc. in Q4 2020 and held it in 7 quarters.
  • Benjamin F. Edwards & Company's Aptose Biosciences, Inc. position peaked at $44K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2022.

Based on Benjamin F. Edwards & Company's 13F filing for Q4 2022, filed 7 Feb 2023.